Vizibl Enters Phase I Partnership with Sanofi
Vizibl and Sanofi have entered into a Phase I partnership to streamline processes around supplier management.
Software-as-a-service (SaaS) platform provider, Vizibl, has announced, in a Sept. 16, 2020 press release, the formation of a Phase I partnership with Sanofi to streamline processes around supplier management.
The partnership will see Sanofi’s key supplier management teams use Vizibl’s Supplier Collaboration and Innovation (SC&I) solution to build more strategic relationships with top tier suppliers. Additionally, Sanofi will use Vizibl to capture continuous improvement and innovation opportunities from suppliers as a part of its supplier nurture program.
“In today’s hyper-dynamic environment, Vizibl enables Sanofi to bring transparency to its supplier relationships and optimize its strategic versus run-the-business activities to make better investment decisions and deliver outstanding growth and value opportunities,” said Mark Perera, CEO at Vizibl, in the press release. “We look forward to changing the world together with Sanofi and cannot wait to see the great results that come out of this relationship for Sanofi’s customers.”
Source: Vizibl
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
